Autoimmune diseaseImmunology & inflammationDermatology Other/Unclassified

Certolizumab pegol subcutaneous PK

Reference paper ↗

A reduced subcutaneous PK model representing certolizumab pegol absorption from a depot, systemic elimination, blood concentration, and cumulative exposure.

Therapeutic
Certolizumab pegol
Modality
Antibody fragment
Target
TNF / TNFA, P01375
Disease
Plaque psoriasis
Model type
Other/Unclassified

Complete model workspace

Checking workspace access…

Parameters
4
States
4
Equations
4
Derived outputs
8

Explore this model

Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.

400 mg single-dose PBPK

How do loading and maintenance regimens shape certolizumab pegol blood concentration and exposure? Explore this intervention regimen through Blood certolizumab concentration, Cumulative certolizumab exposure, Apparent half-life.

Starting result

This result reflects the starting settings. Run your changes to update it.

Result preview could not load

The generated result could not be loaded. The inputs remain available below.

Starting configuration

Time: 0–14.13 day; step 0.2

InputDefaultAvailable range
Bioavailability0.8 dimensionless0.4–1.2 dimensionless
Effective distribution volume3.821 L1.91–5.731 L
Absorption rate constant0.4779 1/day0.239–0.7169 1/day
Elimination rate constant0.06419 1/day0.03209–0.09628 1/day

Expected readouts

Blood certolizumab concentration · Exposure (AUC) (mg*day/L) · Apparent half-life

Adjustable model parameters

This public explorer exposes 4 curated parameters. Sign in to edit all 4 declared model parameters.

How the model represents the biology

A reduced subcutaneous PK model representing certolizumab pegol absorption from a depot, systemic elimination, blood concentration, and cumulative exposure.

How does subcutaneous certolizumab pegol reach blood and accumulate exposure?A subcutaneous certolizumab pegol dose enters a depot, is absorbed into a lumped blood compartment, undergoes first-order elimination, and contributes blood concentration to cumulative exposure.BIOLOGY OVERVIEWHow does subcutaneous certolizumab pegol reach blood and accumulate exposure?Subcutaneous doseCertolizumab pegol inputSC depotFirst-order absorption siteBlood exposureLumped systemic compartmentSystemic lossFirst-order eliminationCumulative exposureBlood concentration integralPRIMARY READOUTSBlood certolizumab concentrationBlood certolizumab concent…Cumulative exposureCumulative exposureDerived half-lifeDerived half-life

Solid arrows show modeled movement or change; two-headed arrows show reversible exchange; dashed arrows show modulation without material transfer.

Model scope: TNF binding or inhibition, psoriasis immune biology, anatomical PBPK tissues, and a QSP network are outside this reduced one-compartment PK model.

Modeled relationships (4)
  • Subcutaneous dose → SC depot: SC input (flow)
  • SC depot → Blood exposure: F · ka (flow)
  • Blood exposure → Systemic loss: first-order (loss)
  • Blood exposure → Cumulative exposure: integrates C (production)

Modeled relationships: Subcutaneous dose to SC depot: SC input (flow); SC depot to Blood exposure: F · ka (flow); Blood exposure to Systemic loss: first-order (loss); Blood exposure to Cumulative exposure: integrates C (production).

Primary readouts: Blood certolizumab concentration; Cumulative exposure; Derived half-life.

Found a scientific issue? Email helpdesk@unibiointelligence.com with model ID coto_segura_2023_certolizumab_pegol_psoriasis_qsp.

Research use only — not for patient-specific prediction or dosing advice.

Ubi Biologics